Download video

Next Generation Antibody Approaches with Aeterna Founder Maria Kondratyev

31 views

RapportIntl

1 month ago

Next Generation Antibody Approaches with Aeterna Founder Maria Kondratyev

Next Generation Antibody Approaches with Aeterna Founder Maria Kondratyev

The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B \& More
5:52
The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B \& More
by OncoAlert 360
Autoantibodies against Mi-2 are highly specific markers for dermatomyositis in primate liver by IIFT
0:14
Autoantibodies against Mi-2 are highly specific markers for dermatomyositis in primate liver by IIFT
by Muhannad Muhammad
Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments
56:54
Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments
by C2N Diagnostics
Myositis Autoantibodies: A Practical Review
3:52
Myositis Autoantibodies: A Practical Review
by TeachMeMedicine.org
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes
1:20
The next steps in antibody development for AD: targeting tau and biomarkers to predict outcomes
by VJDementia
Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti- PL7) antibodies by IIFT.
0:17
Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti- PL7) antibodies by IIFT.
by Muhannad Muhammad
Defining the Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer
15:40
Defining the Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Breast Cancer
by Research To Practice
Insights into a Phase III trial of icotinib for resected EGFR-mutated stage II-IIIA NSCLC
1:07
Insights into a Phase III trial of icotinib for resected EGFR-mutated stage II-IIIA NSCLC
by VJOncology
Exciting New Advances in Biotech! | Introduction to IL-2 Immunotherapy | Medicenna Miniseries Ep. 1
2:46
Exciting New Advances in Biotech! | Introduction to IL-2 Immunotherapy | Medicenna Miniseries Ep. 1
by Medicenna Therapeutics
Top 5 Diseases with A Positive ANA (Antinuclear Antibodies) Test
12:31
Top 5 Diseases with A Positive ANA (Antinuclear Antibodies) Test
by Dr. Diana Girnita - Rheumatologist OnCall
Prof Talks Episode 2: Hyperimmune Responses \& Children's Long COVID – Scientific Insights
35:06
Prof Talks Episode 2: Hyperimmune Responses \& Children's Long COVID – Scientific Insights
by Attomarker
Updates to EPI2ME
11:55
Updates to EPI2ME
by Oxford Nanopore Technologies
Autoantibodies in Juvenile Myositis
4:35
Autoantibodies in Juvenile Myositis
by Cure JM Foundation
LRRK2: A pivotal regulator of neutrophil migration to infection sites
1:51
LRRK2: A pivotal regulator of neutrophil migration to infection sites
by AJE Video Bytes
COVID-19 Triggered Anti-MDA-5 Antibody: Innocent Bystander or Culprit? Dr. Smarika Saptoka at RWCS22
5:32
COVID-19 Triggered Anti-MDA-5 Antibody: Innocent Bystander or Culprit? Dr. Smarika Saptoka at RWCS22
by RheumNow
Introduction to Myositis Specific Antibodies, or MSAs
0:17
Introduction to Myositis Specific Antibodies, or MSAs
by Cure JM Foundation
Current Landscape and Future Directions of Multi-specific Antibodies
44:50
Current Landscape and Future Directions of Multi-specific Antibodies
by Labroots
Myositis-specific antibodies in dermatomyositis: A single-center experience of 33 cas... | RTCL.TV
1:31
Myositis-specific antibodies in dermatomyositis: A single-center experience of 33 cas... | RTCL.TV
by Medicine RTCL TV
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC
1:40
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC
by VJOncology
How Close Are We To The Next Pandemic
4:45
How Close Are We To The Next Pandemic
by RIFOMN
Multicenter Phase II trial evaluates AdAPT-001 for resistant tumors, showing promising efficacy
1:10
Multicenter Phase II trial evaluates AdAPT-001 for resistant tumors, showing promising efficacy
by VJOncology